These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17704517)

  • 41. [Clinical laboratory approach for estimating effective administrative dose of cefoperazone. Evaluation of disc susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1988 Oct; 41(10):1418-29. PubMed ID: 3204655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA; Koch KM; Dowzicky MJ
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of different Mueller-Hinton agars and media age on Etest susceptibility testing of tigecycline.
    Tan TY; Ng LS; Chen DM
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):93-5. PubMed ID: 20727479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical laboratory approach to estimate effective administrative dose of minocyclin. Reevaluation of in vitro MIC break points in disc susceptibility test].
    Uete G; Matsuo K; Uete T
    Jpn J Antibiot; 1990 Sep; 43(9):1545-58. PubMed ID: 2262962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2.
    Tan TY; Ng LS; Poh K
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):357-61. PubMed ID: 17467946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.
    Sotto A; Bouziges N; Jourdan N; Richard JL; Lavigne JP
    Pathol Biol (Paris); 2007 Nov; 55(8-9):398-406. PubMed ID: 17905534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.
    Pillar CM; Draghi DC; Dowzicky MJ; Sahm DF
    J Clin Microbiol; 2008 Sep; 46(9):2862-7. PubMed ID: 18596149
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin.
    Tan TY; Ng SY
    Clin Microbiol Infect; 2007 May; 13(5):541-4. PubMed ID: 17371537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
    Ratnam I; Franklin C; Spelman DW
    Pathology; 2007 Dec; 39(6):586-8. PubMed ID: 18027263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria.
    Andrews JM; Ashby JP; Jevons GM; Wise R
    J Antimicrob Chemother; 1999 Dec; 44(6):819-22. PubMed ID: 10590284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC.
    Torrico M; González N; Giménez MJ; Alou L; Sevillano D; Navarro D; Díaz-Antolín MP; Larrosa N; Aguilar L; Garcia-Escribano N
    J Clin Microbiol; 2010 Jun; 48(6):2243-6. PubMed ID: 20351208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of EUCAST zone diameter breakpoints against reference broth microdilution.
    Bengtsson S; Bjelkenbrant C; Kahlmeter G
    Clin Microbiol Infect; 2014 Jun; 20(6):O353-60. PubMed ID: 24118469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
    Morrissey I; Ge Y; Janes R
    Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the performance characteristics of different antimicrobial susceptibility testing methodologies for testing susceptibility of gram-negative bacteria to tigecycline.
    Babaei S; Haeili M
    BMC Infect Dis; 2021 Jul; 21(1):709. PubMed ID: 34315422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method.
    Potz NA; Mushtaq S; Johnson AP; Henwood CJ; Walker RA; Varey E; Warner M; James D; Livermore DM
    J Antimicrob Chemother; 2004 May; 53(5):729-38. PubMed ID: 15056636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.
    Rose WE; Poppens PT
    J Antimicrob Chemother; 2009 Mar; 63(3):485-8. PubMed ID: 19109338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
    Kratzer C; Rabitsch W; Hirschl AM; Graninger W; Presterl E
    Eur J Haematol; 2007 Nov; 79(5):405-9. PubMed ID: 17714506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.